中文
  • About Us
    Corporate Overview Management Team Board of Directors Contact Us
  • Our Focus
    Metabolic Diseases Exploratory Indications
  • Pipeline
    Pipeline Clinical Trials
  • Partnership
  • Investors
    Financials & Filing
  • News
  • Careers
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • Show More
    2014
  • Ascletis Received IND Approval and Management Outlook of 2019 and Beyond

    2019-08-05

  • Ascletis to Attend Goldman Sachs China Healthcare Corporate Day 2019

    2019-06-24

  • 3-V Biosciences Commences Dosing in Phase 2 Clinical Study of the FASN Inhibitor TVB-2640 in Patients with NASH

    2019-05-02

  • Ganovo is Eligible for the Basic Medical Insurance of Zhejiang Province - Reimbursement-by-disease

    2019-04-15

  • Ascletis and 3-V Biosciences Announce NASH Strategic License and Series E Financing

    2019-02-13

  • Dr. Jinzi J. Wu to Speak at the 19th Annual Conference of China Entrepreneurs Forum

    2019-02-12

  • Dr. Jinzi J. Wu to Speak at the 21st Annual BIO CEO & Investor Conference in New York City

    2019-02-07

  • Ascletis and Alphamab Announce Strategic Collaboration and Licensing Agreement for Anti-PD-L1 to Treat Hepatitis B and Other Viral Diseases

    2019-01-14

  • Ascletis Presented at the LeadingBiotech: East/West CEO

    2019-01-07

  • Ascletis’ IND Filing for Its Third HCV Drug ASC21 Accepted by NMPA

    2019-01-03

  • «
  •  
  • 1
  • 2
  • 3
  •  
  • »
    • © 2018 Ascletis Pharma Inc.
    • All Rights Reserved

    contact

    • pr@ascletis.com
    • bd@ascletis.com
    • hr@ascletis.com
    • clinicaltrials@ascletis.com

    © 2018 Ascletis Pharma Inc. All Rights Reserved
    浙公网安备 33010802003344号 浙ICP备11050387号-1